

CLAIMS

1. Use of IL6RIL6 chimera for the manufacture of a medicament for the treatment and/or prevention of neurological diseases and disorders.
- 5 2. The use according to claim 1, for manufacture of a medicament for treating traumatic nerve degeneration, demyelinating diseases of the CNS or PNS and/or neurodegenerative diseases.
- 10 3. The use according to claim 2, wherein the demyelinating disease is multiple sclerosis (MS).
4. The use of claim 2 wherein the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease and ALS.
- 15 5. A pharmaceutical composition comprising IL6RIL6 chimera, optionally together with one or more pharmaceutically acceptable excipients, for treating and/or preventing of a neurological disease or disorder.
- 20 6. Pharmaceutical composition according to claim 5, comprising IL6RIL6 chimera, optionally together with one or more pharmaceutically acceptable excipients, for treating traumatic nerve degeneration, demyelinating diseases of the CNS or PNS and/or neurodegenerative diseases.
- 25 7. The pharmaceutical composition of claim 6 wherein the demyelinating disease is MS.

8. The pharmaceutical composition of claim 6 wherein the neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease and ALS.
9. A method for treating a neurological disease or disorder comprising administering to
5 a patient in need thereof an effective amount of IL6RIL6 chimera, optionally together with a pharmaceutically acceptable carrier.
10. A method for treating MS, Alzheimer's disease, Parkinson's disease or ALS comprising administering to a patient in need thereof an effective amount of
10 IL6RIL6 chimera, optionally together with a pharmaceutically acceptable carrier.

